ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Services

CMIC Holdings Co., Ltd.

  • 1,957.00 JPY
  • +54.00
  • +2.84%
  • Japan
    Dec 17, 2018
  • Ticker
    TKS(2309)
  • Prev. close
    1,903
  • Market cap (JPY)
    36,011.55M
  • Market cap (USD)
    317.52M
  • Shares
    18.92M

Business Summary

CMIC Holdings Co., Ltd. engages in the provision of support services for pharmaceutical development, manufacturing, and sales. Its operations are carried out through the following segments: Contract Research Organization (CRO), Contract Manufacturing Organization (CMO), Contract Sales Organization (CSO), Health Care, and Intellectual Properties Development (IPD). The CRO segment provides the professional services related to the administration of clinical study and survey upon manufacture and sale such as monitoring, data management, pharmaceutical consulting, and preclinical businesses. The CMO segment handles the contract manufacture of medical supplies for pharmaceutical companies. The CSO segment includes sale and marketing support for pharmaceutical companies. The Health Care segment provides medical and support services for health maintenance and improvement. The IPD segment involves in the development and sale of diagnostic and orphan drugs. The company was founded by Kazuo Nakamura on March 14, 1985 and is headquartered in Tokyo, Japan.

Financial Highlights

Sep 2018 JPYUSD
Revenue69,869M632.50M
Gross Profit14,893M134.82M
Operating income4,337M39.26M
Income before tax3,949M35.74M
Net income1,487M13.46M
EBITDA7,782M70.44M
Diluted EPS79.670.72
Dividends Per Share27.500.24
Total Assets78,034M687.00M
Total liabilities44,495M391.73M
Total equity22,583M198.82M
Operating cash flow7,488M67.78M
Currency in JPYCurrency in USD

Historical Data

 Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018
Revenue 52,836M 55,904M 62,039M 65,282M 69,869M
Gross Profit 10,893M 11,088M 13,098M 14,238M 14,893M
Operating income 2,766M 1,411M 3,365M 3,898M 4,337M
Income before tax 2,467M 1,280M 2,599M 3,269M 3,949M
Net income 1,174M -542M 879M 1,551M 1,487M
EBITDA 4,793M 4,308M 6,485M 7,075M 7,782M
Diluted EPS 65.23 -29.54 46.95 82.87 79.67
Dividends Per Share 35 22.50 16 27.50 27.50
Total Assets 49,237M 55,861M 59,104M 65,605M 78,034M
Total liabilities 28,928M 35,194M 37,704M 41,995M 44,495M
Total equity 20,224M 20,341M 20,996M 22,868M 22,583M
Operating cash flow 2,677M 889M 6,493M 4,933M 7,488M
 Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018
Revenue 516.43M 468.61M 555.62M 586.58M 632.50M
Gross Profit 106.47M 92.94M 117.30M 127.93M 134.82M
Operating income 27.03M 11.82M 30.13M 35.02M 39.26M
Income before tax 24.11M 10.72M 23.27M 29.37M 35.74M
Net income 11.47M -4.54M 7.87M 13.93M 13.46M
EBITDA 46.84M 36.11M 58.08M 63.57M 70.44M
Diluted EPS 0.63 -0.24 0.42 0.74 0.72
Dividends Per Share 0.34 0.18 0.14 0.24 0.24
Total Assets 448.85M 466.42M 583.65M 582.81M 687.00M
Total liabilities 263.71M 293.85M 372.33M 373.07M 391.73M
Total equity 184.36M 169.84M 207.33M 203.15M 198.82M
Operating cash flow 26.16M 7.45M 58.15M 44.32M 67.78M

Valuation Measures

Sep 2018
PER28.75
ROA2.07%
ROE6.54%
Operating margin6.20%
Profit margin2.12%

Key executives

  • Chairman & Chief Executive Officer: Kazuo Nakamura
  • President, COO & Representative Director: Keiko Oishi
  • CFO, Director & Head-Internal Control: Wataru Mochizuki
  • Representative Director & Executive Vice President: Keiko Nakamura
  • Director & Senior Managing Executive Officer: Akihisa Mitake

Shareholders

  • NAKAMURA KAZUO /PERSEUS/ (21.4%)
  • NAKAMURA FAMILY /CMIC/ (21.2%)
  • Dalton Investments LLC (10.3%)
  • Mittleman Investment Management LLC (5.4%)
  • Cmic Holdings Employee Stock Ownership Plan (2.8%)
  • Norges Bank Investment Management (1.8%)
  • Wellington Management Co. LLP (1.3%)
  • The Vanguard Group, Inc. (1.1%)
  • Dimensional Fund Advisors LP (1.1%)
  • Nomura Asset Management Co., Ltd. (0.9%)

Contact Details

Related Companies

  • CMIC Co., Ltd. (New)
  • Cmic Employee Incentive Plan
  • Cimic CMO Ashikaga KK
  • CMIC Korea Co. Ltd.
  • CMIC CMO Korea Co. Ltd.
  • CMIC Asia-Pacific Pte Ltd.
  • CMIC-PMS Co., Ltd.
  • CMIC Bioresearch Center KK
  • CMIC Medical Support KK
  • CMIC Medical Research KK
  • Healthclick Co., Ltd.
  • CMIC CMO USA Corp.
  • CMIC (Beijing) Co., Ltd.
  • Tokyo CRO, Inc. /Data Management Statistics Analysis Ops/
  • Site Support Institute Co. Ltd SSI
  • CMIC CMO Co., Ltd.
  • JCL Bioassay Corporation
  • VPS Corp.
  • Institute of Applied Medicine, Inc.
  • CMIC SS CMO Co., Ltd.
  • Haedong SS Pharmaceutical Ltd.
  • Carenet, Inc. (Japan) /Renkei Kun Business/
  • PCN Corp.
  • Site Support Institute Co., Ltd.
  • Cmic Holdings Employee Stock Ownership Plan

Competitors

  • IQVIA Holdings Inc
Last Updated on 17 Dec, 2018

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

{{sentenceStarter}} {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} this month

Stay ahead with our exclusives on Asia; the most dynamic market in the world.

Benefit from in-depth journalism from trusted experts within Asia itself.

Try 3 months for $9

Offer ends September 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media